Interclean Shanghai

Cardinal Health launches most comprehensive offering for heart imaging agents

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

EU Begins Revision of Medical Device...

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, unveiled an expanded portfolio of cardiac imaging agent products that offers Myoview, Cardiolite and a new generic sestamibi product from Cardinal Health.

The company announced the product portfolio expansion as part of its strategy to broaden choice for its customers.

John Rademacher, president and general manager of Nuclear and Specialty Pharmacy Services for Cardinal Health said, Cardinal Health is now the only company that can offer all three technetium-based heart agents across a national network of nearly 160 nuclear pharmacies.  By increasing choice for our customers, we continue to add differentiated value from our industry leading foundation of service and quality. Although we recognize the serious implications of the current global molybdenum shortage, we believe the introduction of this additional product is an important long-term benefit for nuclear medicine practitioners and their patients. Cardinal Health will continue to work with industry leaders and the Society for Nuclear Medicine to address current, mid-range and long-term solutions for molybdenum supply.

Latest stories

Related stories

EU Begins Revision of Medical Device Regulatory Framework

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »